Your Health, We Care
The US Food and Drug Administration (FDA) has approved the combination standard treatment regimen of Quizartinib for the treatment of adult patients with FLT3-ITD positive AML.
The FDA has approved the LeukoStat CDx FLT3 mutation test as a companion diagnosis for Quizartinib, which helps to more accurately identify patient populations suitable for Quizartinib use.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
